BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, Hu J, Feng D. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. [PMID: 32566610 DOI: 10.21037/atm.2020.03.71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 He J, Sun H, Li F, Yang H, Lou M, Wang S, Wu C. Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real-world study. Hepatol Res 2021;51:1153-63. [PMID: 34492152 DOI: 10.1111/hepr.13708] [Reference Citation Analysis]
2 Lock M, Meyers BM, Mujoomdar A. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard? Ann Transl Med 2021;9:3. [PMID: 33553296 DOI: 10.21037/atm-20-7474] [Reference Citation Analysis]
3 Straś W, Gotlib J, Małkowski P, Wasiak D, Śliwczyński A, Panczyk M, Tronina O, Brzozowska M. Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience. Med Sci Monit 2021;27:e931856. [PMID: 34462415 DOI: 10.12659/MSM.931856] [Reference Citation Analysis]